J05AF05 · Anti-infectives for systemic use
Lamivudine Teva Pharma B.V.
Indications
Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.
Composition
- Active substance
- lamivudine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lamivudine Teva Pharma B.V.
- Active substance
- lamivudine
- ATC code
- J05AF05
- Therapeutic area
- HIV Infections
- Marketing authorisation holder
- Teva B.V.
- Status
- Authorised
- EU authorisation